Effect Of Selective;-adrenoceptor Blockade And Surgical Resection Of The Celiac-superior Mesenteric Ganglion Complex On Delayed Liquid Gastric Emptying Induced By Dipyrone, 4-aminoantipyrine, And Antipyrine In Rats

There is evidence for participation of peripheral β-adrenoceptors in delayed liquid gastric emptying (GE) induced in rats by dipyrone (Dp), 4-aminoantipyrine (AA), and antipyrine (At). The present study aimed to determine whether β-adrenoceptors are involved in delayed GE induced by phenylpyrazole derivatives and the role of the prevertebral sympathetic nervous system in this condition. Male Wistar rats weighing 220-280 g were used in the study. In the first experiment rats were intravenously pretreated with vehicle (V), atenolol 30 mg/kg (ATE, β1-adrenergic antagonist), or butoxamine 25 mg/kg (BUT, β2-adrenergic antagonist). In the second experiment, rats were pretreated with V or SR59230A 2 mg/kg (SRA, β3-adrenergic antagonist). In the third experiment, rats were subjected to surgical resection of the celiac-superior mesenteric ganglion complex or to sham surgery. The groups were intravenously treated with saline (S), 240 µmol/kg Dp, AA, or At, 15 min after pretreatment with the antagonists or V and nine days after surgery. GE was determined 10 min later by measuring the percentage of gastric retention (%GR) of saline labeled with phenol red 10 min after gavage. The %GR (means±SE, n=6) values indicated that BUT abolished the effect of Dp (BUT+Dp vs V+Dp: 35.0%±5.1% vs 56.4%±2.7%) and At (BUT+At vs V+At: 33.5%±4.7% vs 52.9%±2.6%) on GE, and significantly reduced (P<0.05) the effect of AA (BUT+AA vs V+AA: 48.0%±5.0% vs 65.2%±3.8%). ATE, SRA, and sympathectomy did not modify the effects of treatments. These results suggest that β2-adrenoceptor activation occurred in delayed liquid gastric emptying induced by the phenylpyrazole derivatives dipyrone, 4-aminoantipyrine, and antipyrine. Additionally, the released neurotransmitter did not originate in the celiac-superior mesenteric ganglion complex.49

Evidence for the involvement of peripheral -adrenoceptors in delayed liquid gastric emptying induced by dipyrone, 4-aminoantipyrine, and antipyrine in rats

Dipyrone (Dp), 4-aminoantipyrine (AA), and antipyrine (At) delay liquid gastric emptying (GE) in rats. We evaluated adrenergic participation in this phenomenon in a study in male Wistar rats (250-300 g) pretreated subcutaneously with guanethidine (GUA), 100 mg·kg−1·day−1, or vehicle (V) for 2 days before experimental treatments. Other groups of animals were pretreated intravenously (iv) 15 min before treatment with V, prazosin (PRA; 1 mg/kg), yohimbine (YOH; 3 mg/kg), or propranolol (PRO; 4 mg/kg), or with intracerebroventricular (icv) administration of 25 µg PRO or V. The groups were treated iv with saline or with 240 µmol/kg Dp, AA, or At. GE was determined 10 min later by measuring the percentage of gastric retention (%GR) of saline labeled with phenol red 10 min after gavage. %GR (mean±SE, n=8) indicated that GUA abolished the effect of Dp (GUA vs V=31.7±1.6 vs 47.1±2.3%) and of At (33.2±2.3 vs 54.7±3.6%) on GE and significantly reduced the effect of AA (48.1±3.2 vs 67.2±3.1%). PRA and YOH did not modify the effect of the drugs. %GR (mean±SE, n=8) indicated that iv, but not icv, PRO abolished the effect of Dp (PRO vs V=29.1±1.7 vs 46.9±2.7%) and At (30.5±1.7 vs 49±3.2%) and significantly reduced the effect of AA (48.4±2.6 vs 59.5±3.1%). These data suggest activation of peripheral β-adrenoceptors in the delayed GE induced by phenylpyrazolone derivatives.73573

Phenylpyrazolone derivatives inhibit gastric emptying in rats by a capsaicin-sensitive afferent pathway

Dipyrone (Dp), 4-aminoantipyrine (AA) and antipyrine (At) administered iv and Dp administered icv delay gastric emptying (GE) in rats. The participation of capsaicin (Cps)-sensitive afferent fibers in this phenomenon was evaluated. Male Wistar rats were pretreated sc with Cps (50 mg/kg) or vehicle between the first and second day of life and both groups were submitted to the eye-wiping test. GE was determined in these animals at the age of 8/9 weeks (weight: 200-300 g). Ten minutes before the study, the animals of both groups were treated iv with Dp, AA or At (240 μmol/kg), or saline; or treated icv with Dp (4 μmol/animal) or saline. GE was determined 10 min after treatment by measuring % gastric retention (GR) of saline labeled with phenol red 10 min after orogastric administration. Percent GR (mean ± SEM, N = 8) in animals pretreated with Cps and treated with Dp, AA or At (35.8 ± 3.2, 35.4 ± 2.2, and 35.6 ± 2%, respectively) did not differ from the GR of saline-treated animals pretreated with vehicle (36.8 ± 2.8%) and was significantly lower than in animals pretreated with vehicle and treated with the drugs (52.1 ± 2.8, 66.2 ± 4, and 55.8 ± 3%, respectively). The effect of icv administration of Dp (N = 6) was not modified by pretreatment with Cps (63.3 ± 5.7%) compared to Dp-treated animals pretreated with vehicle (62.3 ± 2.4%). The results suggest the participation of capsaicin-sensitive afferent fibers in the delayed GE induced by iv administration of Dp, AA and At, but not of icv Dp.1086108

Effect Of The Gabab Agonist Baclofen On Dipyrone-induced Delayed Gastric Emptying In Rats

Dipyrone administered intravenously (iv) or intracerebroventricularly (icv) delays gastric emptying (GE) in rats. Gamma-aminobutyric acid (GABA) is the most potent inhibitory neurotransmitter of the central nervous system. The objective of the present study was to determine the effect of icv baclofen, a GABAB receptor agonist, on delayed GE induced by dipyrone. Adult male Wistar rats received a saline test meal containing phenol red as a marker. GE was indirectly evaluated by determining the percent of gastric retention (%GR) of the meal 10 min after orogastric administration. In the first experiment, the animals were injected iv with vehicle (Civ) or 80 mg/kg (240 μmol/kg) dipyrone (Dpiv), followed by icv injection of 10 μl vehicle (bac0), or 0.5 (bac0.5), 1 (bac1) or 2 μg (bac2) baclofen. In the second experiment, the animals were injected icv with 5 μl vehicle (Cicv) or an equal volume of a solution containing 4 μmol (1333.2 μg) dipyrone (Dpicv), followed by 5 μl vehicle (bac0) or 1 μg baclofen (bac1). GE was determined 10 min after icv injection. There was no significant difference between control animals from one experiment to another concerning GR values. Baclofen at the doses of 1 and 2 μg significantly reduced mean %GR induced by iv dipyrone (Dpivbac1 = 35.9% and Dpivbac2 = 26.9% vs Dpivbac0 = 51.8%). Similarly, baclofen significantly reduced the effect of dipyrone injected icv (mean %GR: Dpicvbac1 = 30.4% vs Dpicvbac0 = 54.2%). The present results suggest that dipyrone induces delayed GE through a route in the central nervous system that is blocked by the activation of GABAB receptors.38199104Weisbrodt, N.W., Gastric emptying (1997) Gastrointestinal Physiology, pp. 33-42. , Johnson LR (Editor), 5th edn. Mosby, St. Louis, MO, USAWood, J.D., Alpers, D.H., Andrews, P.L.R., Fundamentals of neurogastroenterology (1999) Gut, 45 (SUPPL. II), pp. II6-II-16Collares, E.F., Vinagre, A.M., Evidence of the effect of dipyrone on the central nervous system as a determinant of delayed gastric emptying observed in rats after its administration (2003) Brazilian Journal of Medical and Biological Research, 36, pp. 1375-1382Mody, I., De Konink, Y., Otis, T.S., Soltesz, I., Bridging the cleft at GABA synapses in the brain (1994) Trends in Neurosciences, 17, pp. 517-525Couve, A., Moss, S.J., Pangalos, M.N., GABAB receptors: A new paradigm in G protein signaling (2000) Molecular and Cellular Neurosciences, 16, pp. 296-312Johnston, G.A.R., GABAC receptors: Relatively simple transmitter-gated ion channels? (1996) Trends in Pharmacological Sciences, 17, pp. 319-323Enz, R., Cutting, G.R., Molecular composition of GABAC receptors (1998) Vision Research, 38, pp. 1431-1441Bormann, J., The 'ABC' of GABA receptors (2000) Trends in Pharmacological Sciences, 21, pp. 16-19Sivarao, D.V., Krowicki, Z.K., Hornby, P.J., Role of GABAA receptors in rat hindbrain nuclei controlling gastric motor function (1998) Neurogastroenterology and Motility, 10, pp. 305-313Greenwood-Van Meerveld, B., Barron, K.W., Tonic GABAA receptor-mediated neurotransmission in the dorsal vagal complex regulates intestinal motility in rats (1998) European Journal of Pharmacology, 346, pp. 197-202Brooks, P.A., Glaum, S.R., Miller, R.J., Spyer, K.M., The actions of baclofen on neurones and synaptic transmission in the nucleus tractus solitarii of the rat in vitro (1992) Journal of Physiology, 457, pp. 115-129Bertolino, M., Kellar, K.J., Vicini, S., Gillis, R.A., Nicotinic receptor mediates spontaneous GABA release in the rat dorsal motor nucleus of the vagus (1997) Neuroscience, 79, pp. 671-681Yuan, C.-S., Liu, D., Attele, A.S., GABA-ergic effects on nucleus tractus solitarius neurons receiving gastric vagal inputs (1998) Journal of Pharmacology and Experimental Therapeutics, 286, pp. 736-741Bowery, N.G., GABAB receptor pharmacology (1993) Annual Review of Pharmacology and Toxicology, 33, pp. 109-147Goto, Y., Tache, Y., Debas, H., Novin, D., Gastric acid and vagus nerve response to GABA agonist baclofen (1985) Life Sciences, 36, pp. 2471-2475Andrews, P.L.R., Wood, K.L., Systemic baclofen stimulates gastric motility and secretion via a central action in the rat (1986) British Journal of Pharmacology, 89, pp. 461-467de Groot, T., (1959) The Rat Forebrain in Stereotaxic Coordinates, , NV Noord-Holand Witgevers, Amsterdam, The NetherlandsBucaretchi, F., Collares, E.F., Effect of Phoneutria nigriventer spider venom on gastric emptying in rats (1996) Brazilian Journal of Medical and Biological Research, 29, pp. 205-211Singh, R., Ticku, M.K., Central cardiovascular effects of baclofen in spontaneously hypertensive rats (1987) Life Sciences, 40, pp. 1017-1026Bowery, N.G., Hudson, A.L., Price, G.W., GABAA and GABAB receptor site distribution in the rat central nervous system (1987) Neuroscience, 20, pp. 365-383Chu, D.C.M., Albin, R.L., Young, A.B., Penney, J.B., Distribution and kinetics of GABAB binding sites in rat central nervous system: A quantitative autoradiographic study (1990) Neuroscience, 34, pp. 341-357Misgeld, U., Bijak, M., Jarolimek, W., A physiological role for GABAB receptors and the effects of baclofen in the mammalian central nervous system (1995) Progress in Neurobiology, 46, pp. 423-462Scanziani, M., GABA spillover activates postsynaptic GABAB receptors to control rhythmic hippocampal activity (2000) Neuron, 25, pp. 673-681Pratt, G.D., Bowery, N.G., Autoradiography of GABA receptor binding sites in the dorsal vagal complex of the rat hindbrain (1992) British Journal of Pharmacology, 107 (SUPPL.), pp. 211P. , (Abstract)Williford, D.J., Ormsbee III, H.S., Norman, W., Harmon, J.W., Garvey III, T.Q., DiMicco, J.A., Gillis, R.A., Hindbrain GABA receptors influence parasympathetic outflow to the stomach (1981) Science, 214, pp. 193-194Herman, J.P., Cullinan, W.E., Neurocircuitry of stress: Central control of the hypothalamo-pituitary-adrenocortical axis (1997) Trends in Neurosciences, 20, pp. 78-84Bäckberg, M., Collin, M., Ovesjö, M.-L., Meister, B., Chemical coding of GABAB receptor-immunoreactive neurones in hypothalamic regions regulating body weight (2003) Journal of Neuroendocrinology, 15, pp. 1-14Kapp, B.S., Schwaber, J.S., Driscoll, P.A., The organization of insular cortex projections to the amygdaloid central nucleus and autonomic regulatory nuclei of dorsal medulla (1985) Brain Research, 360, pp. 355-360Aleksandrov, V.G., Bagaev, V.A., Nozdrachev, A.D., Panteleev, S.S., Identification of gastric related neurones in the rat insular cortex (1996) Neuroscience Letters, 216, pp. 5-8Liubashina, O., Jolkkonen, E., Pitkänen, A., Projections from the central nucleus of the amygdala to the gastric related area of the dorsal vagal complex: A Phaseolus vugaris-leucoagglutinin study in rat (2000) Neuroscience Letters, 291, pp. 85-88Liubashina, O., Bagaev, V., Khotiantsev, S., Amygdalofugal modulation of vago-vagal gastric motor reflex in the rat (2002) Neuroscience Letters, 325, pp. 183-186Doretto, M.C., Garcia-Cairasco, N., Pimenta, N.J.G., Souza, D.A., Tatsuo, M.A.K.F., Dipyrone, a novel anticonvulsant agent? Insights from three experimental epilepsy models (1998) NeuroReport, 9, pp. 2415-2421Ergün, H., Uzbay, I.T., Çelik, T., Kayir, H., Yesilyurt, Ö., Tulunay, F.C., Dipyrone inhibits ethanol withdrawal and pentylenetetrazol-induced seizures in rats (2001) Drug Development Research, 53, pp. 254-259Tossman, U., Jonsson, G., Ungerstedt, U., Regional distribution and extracellular levels of amino acids in rat central nervous system (1986) Acta Physiologica Scandinavica, 127, pp. 533-54

Effect of antipyrine on the gastric emptying of liquid in rats

Antipyrine (At) and dipyrone (Dp) delay gastric emptying (GE) in rats. The objective of the present study was to assess the effects of intravenous (iv) and intracerebroventricular (icv) administration of At and Dp on the GE of liquid by rats. GE was assessed in male Wistar rats (5-10 in each group) 10 min after the icv or iv drug injection by measuring percent gastric retention (%GR) of a saline test meal labeled with phenol red 10 min after administration by gavage. The At iv group was significantly higher (64.4 ± 2.6%) compared to control (33.4 ± 1.5%) but did not differ from the Dp group (54.3 ± 3.8%). After icv administration of At, %GR (34.2 ± 2%) did not differ from control (32.6 ± 1.9%), but was significantly higher after Dp (54.5 ± 2.3%). Subdiaphragmatic vagotomy significantly reduced %GR in the At group (30.2 ± 0.7%) compared to the sham group, but was significantly higher than in the controls (23.0 ± 0.5%). In the animals treated with At iv, baclofen significantly reduced %GR (28.3 ± 2.4%) compared to vehicle-treated animals (55.2 ± 3.2%). The same occurred in the animals treated iv with vehicle and icv with baclofen. Although vagotomy and baclofen reduced %GR per se, the reduction was twice more marked in the animals treated with At. The results suggest that At administered iv, but not icv, delays GE of liquid in rats with the participation, at least in part, of the vagus nerve and that this phenomenon is blocked by the activation of GABA B receptors in the central nervous system.1507151

Pulsed Direct And Constant Direct Currents In The Pilocarpine Iontophoresis Sweat Chloride Test

Background: The classic sweat test (CST) is the golden standard for cystic fibrosis (CF) diagnosis. Then, our aim was compare the production and volume of sweat, and side effects caused by pulsed direct current (PDC) and constant direct current (CDC). To determine the optimal stimulation time (ST) for the sweat collection. To verify the PDC as CF diagnosis option. Methods: Prospective study with cross-sectional experimental intervention. Experiment 1 (right arm): PDC and CDC. ST at 10 min and sweat collected at 30 min. Currents of 0.5; 0.75; 1.0 and 1.5 mA and frequencies of 0, 200, 1,000 and 5,000 Hz applied. Experiment 2 (left arm): current of 1.0 mA, ST at 5 and 10 min and sweat collected at 15 and 30 min with frequencies of 0; 200; 1,000 and 5,000 Hz applied Experiments 1 and 2 were performed with current density (CD) from 0.07 to 0.21 mA/cm2. Experiment 3: PDC was used in typical CF patients with two CFTR mutations screened and or with CF diagnosis by rectal biopsy and patients with atypical CF. Results: 48 subjects (79.16% female) with average of 29.54 ± 8.87 years old were enrolled. There was no statistical difference between the interaction of frequency and current in the sweat weight (p = 0.7488). Individually, positive association was achieved between weight sweat and stimulation frequency (p = 0.0088); and current (p = 0.0025). The sweat production was higher for 10 min of stimulation (p = 0.0023). The sweat collection was better for 30 min (p = 0.0019). The skin impedance was not influenced by ST and sweat collection (p > 0.05). The current frequency was inversely associated with the skin impedance (p < 0.0001). The skin temperature measured before stimulation was higher than after (p < 0.0001). In Experiment 3 (29 subjects) the PDC showed better kappa index compared to CDC (0.9218 versus 0.5205, respectively). Conclusions: The performance of the CST with CDC and PDC with CD of 0.14 to 0.21 mA/cm2 showed efficacy in steps of stimulation and collection of sweat, without side effects. The optimal stimulation time and sweat collection were, respectively, 10 and 30 min.141Di Sant'S Agnese, P.A., Darling, R.C., Perara, G.A., Shea, E., Abnormal electrolyte composition of sweat in cystic fibrosis of the pancreas (1953) Am J Dis Child, 86, pp. 618-619Gibson, L.E., Cooke, R.E., A test for concentration of electrolytes in sweat in cystic fibrosis of the pancreas utilizing pilocarpine by iontophoresis (1959) Pediatrics, 23, pp. 545-549Taylor, C.J., Hardcastle, J., Southern, K.W., Physiological measurements confirming the diagnosis of cystic fibrosis. The sweat test and measurements of transepithelial potential difference (2009) Paedia Resp Rev, 10, pp. 220-226Rosenstein, B.J., What is a cystic fibrosis diagnosis? (1998) Clin Chest Med, 19, pp. 423-441Rowe, S.M., Miller, S., Sorscher, E.J., Cystic fibrosis (2005) N Engl J Med, 352, pp. 1992-2001Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation Consensus Report (2008) J Pediatr, 153, pp. S4-e14Castellani, C., Southern, K.W., Brownlee, K., DankertRoelse, J., Duff, A., Farrell, M., Mehta, A., Elborn, S., European best practice guidelines for cystic fibrosis neonatal screening (2009) J Cystic Fibrosis, 8, pp. 153-173Quinton, P.M., Cystic fibrosis: lesson from the sweat gland (2007) Physiology (Bethesda), 22, pp. 212-225Quinton, P.M., Chloride impermeability in cystic fibrosis (1983) Nature, 301, pp. 421-422Collie, J.T.B., Massie, R.J., Jones, O.A.H., LeGrys, V.A., Greaves, R.F., Sixty-Five Years Since the New York Heat Wave: Advances in Sweat Testing for Cystic Fibrosis (2014) Pediatr Pulmonol, 49, pp. 106-117Legrys, V.A., Sweat testing for the diagnosis of cystic fibrosis. Practical considerations (1996) J Pedia, 129, pp. 892-897Gonçalves, A.C., Marson, F.A.L., Mendonça, R.M.H., Ribeiro, J.D., Ribeiro, A.F., Paschoal, I.A., Levy, C.E., Saliva as a potential tool for cystic fibrosisdiagnosis (2013) Diagn Pathol, 8, p. 46Webster, H.L., A clinical appraisal of cystic fibrosis sweat-testing guidelines (2001) Am Clin Lab, 20, pp. 39-42Hammond, K.B., Nelson, L., Gibson, L.E., Clinical evaluation of the macroduct sweat collection system and conductivity analyzer in the diagnosis of cystic fibrosis (1994) J Pediatr, 124, pp. 255-260Portaria N° 288, 21 de Março de 2013. Diário oficial da união, Brasília, N° 56 - DOU - 22/03/13 - seção 1 , p. 47. , ftp://ftp.saude.sp.gov.br/ftpsessp/bibliote/informe_eletronico/2013/iels.mar.13/Iels55/U_PT-MS-SAS-288_210313.pdf, BrasilNumajiri, S., Sakurai, H., Sugibayashi, K., Morimoto, Y., Omiya, H., Takenaka, H., Akiyama, N., Comparison of depolarizing and direct current systems on iontophoretic enhancement of transport of sodium benzoate through human and hairless rat skin (1993) J Pharm Pharmcol, 45, pp. 610-613Zakzewski, C.A., Amory, D.W., Jasaitis, D.K., Li, J.K.J., Iontophoretically enhanced transdermal delivery of an ACE inhibitor in induced hypertensive rabbits: preliminary report (1992) CardiovascularDrugs and Therapy, 6, pp. 589-595Bagniefski, T.M., Burnette, R.R., A comparison of pulsed and continuous current iontophoresis (1990) J Cont Release, 11, pp. 113-122Preat, V., Thysman, S., Trandermaliontophoreric delivery of sulfentanilInt (1993) J Pharmaceut, 96, pp. 189-196(2000) Obesity: Preventing and managing the global epidemic, , Geneva: World Health Organization Technical Support Series, 894, Geneva: World Health OrganizationSousa, M., Servidoni, M.F., Vinagre, A.M., Ramalho, A.S., Bonadia, L.C., Felício, V., Ribeiro, M.A., Amaral, M.D., Measurements of CFTR-mediated Cl- secretion in human rectal biopsies constitute a robust biomarker for Cystic Fibrosis diagnosis and prognosis (2012) Plos One, 7, p. e47708Carlsson, A.M., Assessment of chronic pain. I. Aspects of the reliability and validity of the visual analogue scale (1983) Pain, 16, pp. 87-101Rosenstein, B.J., Cutting, G.R., The diagnosis of cystic fibrosis: a consensus statement. Cystic Fibrosis Foundation Consensus Panel (1998) J Pediatr, 132, pp. 589-595Karezeski, B., Cutting, G., Diagnosis of cystic fibrosis. CFTR-related disease and screening (2006) ProgRespir Res, 34, pp. 69-76Strausbaugh, S.D., Davis, P.B., Cystic fibrosis: a review of epidemiology and pathobiology (2007) Clin Chest Med, 28, pp. 279-288Mackay, R., George, P., Kirk, J., Sweat testing for cystic fibrosis: A review of New Zealand laboratories (2006) J Paedia Child Health, 42, pp. 160-164Cirilli, N., Podan, R., Raia, V., Audit of sweat testing: A first report from Italian cystic fibrosis centres (2008) J Cystic Fibrosis, 7, pp. 415-422Kirk, J.M., Inconsistencies in sweat testing in UK laboratories (2000) Arch Dis Child, 82, pp. 425-427Webster, H.L., Laboratory diagnosis of cystic fibrosis (1983) CRC Crit Rev in Clin LabSci, 18, pp. 313-338http://www.wescor.com/biomedical/cysticfibrosis/macroduct.htmlSabbahi, M.A., Costello, C.T., Ernran, A., A method for reducing skin irritation by iontophoresis (1994) PhysTher, 74, p. S156Su, M.H., Srinivasan, V., Ghanem, A.H., Higuchi, W.I., Quantitative in vivo iontophoreticstudies (1994) J Pharm Sci, 83, pp. 12-17Huang, Y.-Y., Wu, S.-M., Transdermal Iontophoretic Delivery of Thyrotropin-Releasing Hormone Across Excised Rabbit Pinna Skin Drug Dev (1996) Ind Pharm, 22, pp. 1075-1081Knoblauch, P., Moll, F., In vitro pulsatile and continuous transdermal delivery of buserelin by iontophoresis (1993) J Control Release, 26, pp. 203-212Okabe, K., Yamaguchi, H., Kawai, Y., New iontophoretic transdermal administration of the beta-blocker metoprolol (1986) J Control Release, 4, pp. 79-85Li, S.K., Higuchi, W.I., Zhu, H., Kern, S.E., Miller, D.J., Hastings, M.S., In vitro and in vivo comparisons of constant resistance AC iontophoresis and DC iontophoresis (2003) J Control Release, 91, pp. 327-343Banga, A.K., Chien, Y.W., Iontophoretic delivery of drugs: fundamentals, developments and biomedical application (1988) J Control Rel, 7, p. 1Panzade, P., Heda, A., Puranik, P., Patni, M., Mogal, V., Enhanced Transdermal Delivery of Granisetron by Using Iontophoresis (2012) IJPR, 11, pp. 503-512Chen, L.L.H., Chien, Y.W., Transdermal iontophoretic permeation of luteinizing hormone releasing hormone: characterization of electric parameters (1996) J Control Release, 40, pp. 187-198Chien, Y.W., Siddiqui, O., Shi, W.M., Lelawongs, P., Liu, J.C., Direct current iontophoretic transdermal delivery of peptide and protein drugs (1989) J Pharm Sci, 78, pp. 376-383Hirvonen, J., Hueber, F., Guy, R.H., Current profile regulates iontophoretic delivery of amino acids across the skin (1995) J Control Release, 37, pp. 239-249Kanebako, M., Inagi, T., Takayama, K., Transdermal delivery of iondomethacin by iontophoresis (2002) Biol Pharm Bull, 25, pp. 779-782Abramowitz, D., Neoussikine, B., (1946) Treatment by Ion Transfer, p. 87. , NewYork: Grune and StrattonLeGrys, V.A., Applequist, R., Briscoe, D.R., Farrell, P., Hickstein, R., Lo, S.F., Passarell, R., Vaks, J.E., Sweat testing: sample collection and quantitative chloride analysisapproved guidelines - Third Edition (2009) Clin Lab Stand Ins, 29. , C34-A2Beauchamp, M., Lands, L.C., Sweat-Testing: A Review of Current Technical Requirements (2005) Pediatr Pulmonol, 39, pp. 507-511Chiang, C.H., Shao, C.H., Chen, J.L., Effects of pH electric current, and enzyme inhibitors on iontophoresis of delta sleep-inducing peptide (1998) Drug Dev Ind Pharm, 24, pp. 431-438Van der Geest, R., Banhof, M., Bodde, H.E., Iontophoretic delivery of apomorphine I. In-vitro optimization and validation (1997) Pharm Res, 14, pp. 1798-1803Heap, S., Guidelines for the Performance of the Sweat Test for the Investigation of Cystic Fibrosis in the UK 2nd Version. An Evidence Based Guideline (2014) R College Paediatr Child Health, 2, pp. 1-121Kalia, Y.N., Naik, A., Garrison, J., Guy, R.H., Iontophoretic drug delivery (2004) Adv Drug DelivVer, 56, pp. 619-658Barry, B.W., Drug delivery routes in skin: a novel approach (2002) Adv Drug Deliv Rev, 54, pp. S31-S40Pikal, M.J., The role of electroosmotic flow in transdermal iontophoresis (1992) Adv Drug Deliv Rev, 9, pp. 201-237Curdy, C., Kalia, Y.N., Guy, R.H., Post-iontophoresis recovery of human skin impedance in vivo (2002) Eur J Pharm Biopharm, 53, pp. 15-21Ulreich, A., Leibrecht, W., Promer, M., Kullich, W., Infiltration versus iontophoresis in case of epicondylitis. A comparative study. Physikalische Medizin Rehabilitations medizin (1996) Kurortmedizin, 6, pp. 183-185Bolfe, V.J., Ribas, S.I., Montebelo, M.I.L., Guirro, R.R.J., Comportamento da impedância elétrica dos tecidos biológicos durante a estimulação elétrica transcutânea (2007) Rev Bras Fisioter, 11, pp. 153-159Bioelectrical impedance analysis-part I: review of principles and methods (2004) ClinNutr, 23, pp. 1226-1243Nakakura, M., Kato, Y., Hayakawa, E., Kuroda, T., Effect of pulse on iontophoretic delivery of desmopressin acetate in rats (1996) Biol Pharm Bull, 19, pp. 738-740Sagi-Dolev, A.M., Prutchi, D., Nathan, R.H., Three-dimensional current density distribuition under surface stimulation electrodes (1995) Med Biol Eng Comp, 33, pp. 403-408Zhu, F., Scheditz, D., Levin, N.W., Estimation of trunk extracellular volume by bioimpedance (1998) Conf Proc IEEE Eng Med Biol Soc, 20, pp. 3104-3107Chizmadzhev, Y.A., Kuzmin, P.I., Weaver, J.C., Potts, R.O., Skin appendageal macropores as a possible pat way for electrical current (1998) J Investg Dermatol Symp Proc, 3 (2), pp. 148-152Ya-Xian, R.O., Suetake, T., Tagami, H., Number of cell layers of the stratum corneum in normal skin-relationship to the anatomical location on the body, age, sex and physical parameters (1999) Arch Dermatol Res, 291, pp. 555-559Nelson, R.M., Hayes, K.W., Currier, D.P., (1999) Clinical Electrotherapy, pp. 15-54. , 3a. ed. Stanford: Appleton & LangeLow, J., Reed, A., (2000) Electrotherapy Explained: Principles and Practice, , Oxford: Butterworth-HeinemannCameron, M.H., (1999) Physical Agents in Rehabilitation: From Research to Practice, , Philadelphia: W.B.Saunders companyKubisz, L., The influence of storage time on the temperature dependence of the dc electrical conductivity of horn kereatin (2001) Bioelectrochemistry, 53, pp. 161-16

Effectiveness of an mHealth intervention combining a smartphone app and smart band on body composition in an overweight and obese population: Randomized controlled trial (EVIDENT 3 study)

Background: Mobile health (mHealth) is currently among the supporting elements that may contribute to an improvement in health markers by helping people adopt healthier lifestyles. mHealth interventions have been widely reported to achieve greater weight loss than other approaches, but their effect on body composition remains unclear. Objective: This study aimed to assess the short-term (3 months) effectiveness of a mobile app and a smart band for losing weight and changing body composition in sedentary Spanish adults who are overweight or obese. Methods: A randomized controlled, multicenter clinical trial was conducted involving the participation of 440 subjects from primary care centers, with 231 subjects in the intervention group (IG; counselling with smartphone app and smart band) and 209 in the control group (CG; counselling only). Both groups were counselled about healthy diet and physical activity. For the 3-month intervention period, the IG was trained to use a smartphone app that involved self-monitoring and tailored feedback, as well as a smart band that recorded daily physical activity (Mi Band 2, Xiaomi). Body composition was measured using the InBody 230 bioimpedance device (InBody Co., Ltd), and physical activity was measured using the International Physical Activity Questionnaire. Results: The mHealth intervention produced a greater loss of body weight (–1.97 kg, 95% CI –2.39 to –1.54) relative to standard counselling at 3 months (–1.13 kg, 95% CI –1.56 to –0.69). Comparing groups, the IG achieved a weight loss of 0.84 kg more than the CG at 3 months. The IG showed a decrease in body fat mass (BFM; –1.84 kg, 95% CI –2.48 to –1.20), percentage of body fat (PBF; –1.22%, 95% CI –1.82% to 0.62%), and BMI (–0.77 kg/m2, 95% CI –0.96 to 0.57). No significant changes were observed in any of these parameters in men; among women, there was a significant decrease in BMI in the IG compared with the CG. When subjects were grouped according to baseline BMI, the overweight group experienced a change in BFM of –1.18 kg (95% CI –2.30 to –0.06) and BMI of –0.47 kg/m2 (95% CI –0.80 to –0.13), whereas the obese group only experienced a change in BMI of –0.53 kg/m2 (95% CI –0.86 to –0.19). When the data were analyzed according to physical activity, the moderate-vigorous physical activity group showed significant changes in BFM of –1.03 kg (95% CI –1.74 to –0.33), PBF of –0.76% (95% CI –1.32% to –0.20%), and BMI of –0.5 kg/m2 (95% CI –0.83 to –0.19). Conclusions: The results from this multicenter, randomized controlled clinical trial study show that compared with standard counselling alone, adding a self-reported app and a smart band obtained beneficial results in terms of weight loss and a reduction in BFM and PBF in female subjects with a BMI less than 30 kg/m2 and a moderate-vigorous physical activity level. Nevertheless, further studies are needed to ensure that this profile benefits more than others from this intervention and to investigate modifications of this intervention to achieve a global effect